Looking for the high way in EGFR-positive non-small cell lung cancer through the evaluation of survival endpoints

Eitemau Tebyg

• Brain metastases in EGFR-positive non-small cell lung cancer: the way to the sanctuary becomes less winding
  gan: Passaro, Antonio, et al.
  Cyhoeddwyd: (2019)
• Dacomitinib in EGFR-positive non-small cell lung cancer: an attractive but broken option
  gan: Passaro, Antonio, et al.
  Cyhoeddwyd: (2018)
• Adjuvant EGFR TKIs in NSCLC harboring EGFR mutations: looking for a consensus way
  gan: Attili, Ilaria, et al.
  Cyhoeddwyd: (2020)
• Afatinib as first-line treatment for patients with advanced non-small-cell lung cancer harboring EGFR mutations: focus on LUX-Lung 3 and LUX-Lung 6 phase III trials
  gan: Passaro, Antonio, et al.
  Cyhoeddwyd: (2013)
• Erlotinib as standard adjuvant therapy for resectable EGFR mutation-positive non-small cell lung cancer
  gan: Tanaka, Satomi, et al.
  Cyhoeddwyd: (2019)